Clearside Biomedical (CLSD) Competitors $1.01 -0.01 (-0.98%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CLSD vs. MRKR, EYEN, DSGN, ACB, URGN, PRQR, ACIU, QURE, BTMD, and GNFTShould you be buying Clearside Biomedical stock or one of its competitors? The main competitors of Clearside Biomedical include Marker Therapeutics (MRKR), Eyenovia (EYEN), Design Therapeutics (DSGN), Aurora Cannabis (ACB), UroGen Pharma (URGN), ProQR Therapeutics (PRQR), AC Immune (ACIU), uniQure (QURE), biote (BTMD), and Genfit (GNFT). These companies are all part of the "pharmaceutical products" industry. Clearside Biomedical vs. Marker Therapeutics Eyenovia Design Therapeutics Aurora Cannabis UroGen Pharma ProQR Therapeutics AC Immune uniQure biote Genfit Clearside Biomedical (NASDAQ:CLSD) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings. Do analysts rate CLSD or MRKR? Clearside Biomedical presently has a consensus price target of $5.17, suggesting a potential upside of 411.55%. Marker Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 419.13%. Given Marker Therapeutics' higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Clearside Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clearside Biomedical 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in CLSD or MRKR? 18.8% of Clearside Biomedical shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 9.2% of Clearside Biomedical shares are held by company insiders. Comparatively, 17.4% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor CLSD or MRKR? In the previous week, Clearside Biomedical had 3 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for Clearside Biomedical and 0 mentions for Marker Therapeutics. Clearside Biomedical's average media sentiment score of 0.49 beat Marker Therapeutics' score of 0.00 indicating that Clearside Biomedical is being referred to more favorably in the media. Company Overall Sentiment Clearside Biomedical Neutral Marker Therapeutics Neutral Which has more volatility and risk, CLSD or MRKR? Clearside Biomedical has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Which has better earnings and valuation, CLSD or MRKR? Marker Therapeutics has lower revenue, but higher earnings than Clearside Biomedical. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClearside Biomedical$7.52M10.03-$32.49M-$0.50-2.02Marker Therapeutics$3.31M9.86-$8.24MN/AN/A Does the MarketBeat Community favor CLSD or MRKR? Clearside Biomedical received 293 more outperform votes than Marker Therapeutics when rated by MarketBeat users. Likewise, 67.59% of users gave Clearside Biomedical an outperform vote while only 63.72% of users gave Marker Therapeutics an outperform vote. CompanyUnderperformOutperformClearside BiomedicalOutperform Votes36567.59% Underperform Votes17532.41% Marker TherapeuticsOutperform Votes7263.72% Underperform Votes4136.28% Is CLSD or MRKR more profitable? Marker Therapeutics has a net margin of -278.27% compared to Clearside Biomedical's net margin of -444.66%. Clearside Biomedical's return on equity of 0.00% beat Marker Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Clearside Biomedical-444.66% N/A -93.90% Marker Therapeutics -278.27%-78.91%-66.10% SummaryClearside Biomedical beats Marker Therapeutics on 9 of the 15 factors compared between the two stocks. Ad Opportunistic TraderMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicted the 2020 crash a month before it happened...For a limited time, he's revealing his latest forecast here. Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLSD vs. The Competition Export to ExcelMetricClearside BiomedicalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.48M$7.42B$5.50B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-2.0210.05116.1015.23Price / Sales10.03400.761,496.2597.74Price / CashN/A47.3939.7434.10Price / Book-4.045.594.775.07Net Income-$32.49M$153.56M$119.06M$225.46M7 Day Performance-8.18%0.13%0.80%0.37%1 Month Performance-24.63%15.23%5.65%3.57%1 Year Performance26.25%41.14%36.75%29.43% Clearside Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLSDClearside Biomedical2.1503 of 5 stars$1.01-1.0%$5.17+411.6%+32.4%$75.48M$7.52M-2.0230Gap DownMRKRMarker Therapeutics3.5627 of 5 stars$4.05-0.5%$19.00+369.1%+28.9%$36.14M$3.31M0.0060EYENEyenovia2.9442 of 5 stars$0.49-7.5%$12.00+2,347.0%-63.9%$26.42M$31,405.00-0.6140DSGNDesign Therapeutics1.4232 of 5 stars$5.24-5.9%$7.00+33.6%+157.4%$296.69MN/A-5.8240Positive NewsACBAurora Cannabis0.7297 of 5 stars$5.42-4.6%N/A+22.3%$295.64M$278.98M-7.741,073Upcoming EarningsURGNUroGen Pharma3.98 of 5 stars$12.26-5.8%$48.38+294.6%+7.4%$287.55M$85.01M-3.74200Upcoming EarningsPRQRProQR Therapeutics3.0395 of 5 stars$3.50-4.4%$5.88+67.9%+221.6%$285.88M$15.41M-12.07180Upcoming EarningsAnalyst UpgradeACIUAC Immune3.1595 of 5 stars$2.84-4.4%$12.00+322.5%+1.7%$280.87M$15.49M-3.94140Short Interest ↓News CoveragePositive NewsQUREuniQure2.2854 of 5 stars$5.72-9.2%$19.50+240.9%+1.7%$278.56M$15.84M-0.96500Upcoming EarningsBTMDbiote3.9719 of 5 stars$5.10-0.4%$8.39+64.5%-1.9%$276.51M$187.23M30.00194Short Interest ↓GNFTGenfit1.5162 of 5 stars$5.53-5.5%$13.00+135.1%+94.8%$276.16M$76.06M0.00120Short Interest ↑News Coverage Related Companies and Tools Related Companies Marker Therapeutics Competitors Eyenovia Competitors Design Therapeutics Competitors Aurora Cannabis Competitors UroGen Pharma Competitors ProQR Therapeutics Competitors AC Immune Competitors uniQure Competitors biote Competitors Genfit Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CLSD) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearside Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.